How do oncolytic viruses make checkpoint inhibitors more effective?
Oncolytic viruses work by infecting and killing tumor cells directly, but their bigger value is that they turn 'cold' tumors—those with few immune cells—into 'hot' tumors that checkpoint inhibitors can recognize and attack. A 2025 review explains that oncolytic viruses increase the density of CD8+ T-cells (the immune cells that kill cancer) inside tumors, shifting the tumor microenvironment from cold to hot, which then synergizes with checkpoint inhibitors to activate anti-tumor immunity [4]. This mechanism is supported by a 2024 mouse study showing that injecting an oncolytic virus into one tumor increased CD4+ and CD8+ T-cell infiltration in both the injected and distant tumors, and expanded tumor-specific T-cell clones, meaning the virus primes the immune system to fight the cancer systemically [5].
The practical result is that the combination can rescue patients who don't respond to checkpoint inhibitors alone. In a 2021 neoadjuvant trial (treatment before surgery) in acral melanoma—a subtype that responds poorly to checkpoint inhibitor monotherapy—combining an oncolytic virus (OrienX010) with the anti-PD-1 drug toripalimab produced a pathologic response (tumor shrinkage seen under a microscope) in 81% of patients who underwent surgery, with 14% achieving a complete pathologic response (no cancer cells left) [1]. This is a dramatic improvement over the typical response rates of checkpoint inhibitors alone in acral melanoma, which are often below 20%.
Can oncolytic viruses overcome resistance to checkpoint inhibitors?
Yes, and this is one of the most promising angles. A 2021 laboratory study found that melanomas with mutations in the IFNγ-JAK-STAT pathway—a known mechanism of resistance to checkpoint inhibitors—became 7- to 22-fold more sensitive to two different oncolytic viruses (herpes simplex virus and vesicular stomatitis virus) compared to non-resistant cells [3]. This means that the very mutations that make a tumor resistant to immunotherapy may make it more vulnerable to oncolytic viruses, offering a salvage strategy for patients who progress on checkpoint inhibitors.
The same study estimated that about 11% of untreated cutaneous melanomas have alterations in this pathway, suggesting a sizable subset of patients could benefit from this approach [3]. It also supports combining JAK inhibitors (drugs that block the same pathway) with oncolytic viruses for patients without these mutations, as a way to artificially induce sensitivity [3]. This is a precision-medicine approach: instead of using oncolytic viruses for everyone, you could select patients based on their tumor's genetic profile.
What are the caveats and risks?
The combination is not without side effects, and the evidence is still early. In the 2021 neoadjuvant trial, all patients experienced at least one treatment-related adverse event, with grade 1 fever being the most common; 10% had grade 3-4 events (serious, like liver enzyme elevation or wound infections) [1]. A 2022 study on frailty in older melanoma patients found that while frailty didn't increase the risk of severe immune-related side effects, frail patients were hospitalized for these side effects significantly more often (54% vs 29% for fit patients) [2]. This suggests that patient selection and monitoring are important, especially in older or frail patients.
Another caveat is that oncolytic viruses alone have modest efficacy, and the immune response they trigger is not entirely tumor-specific. A 2024 mouse study found that a significant proportion of T-cells in 'hot' tumors after oncolytic virus therapy were actually anti-viral, not anti-tumor, which could limit the effectiveness of the combination [5]. This highlights the need for engineering viruses to favor anti-tumor immunity, as noted in a 2026 review [6]. Overall, the combination is promising, but it's not a magic bullet—it works best in specific contexts, and more research is needed to optimize dosing, patient selection, and to manage side effects.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2026, 3 from 2024 or later, 6 in Q1 journals, collectively cited 124 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 68 papers retrieved from a database of over 500 million.
Sources used in this answer
A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.
In a phase Ib neoadjuvant trial of 30 patients with resectable acral melanoma, combining oncolytic virus OrienX010 with toripalimab produced a pathologic response in 81% of the 21 patients who underwent surgery, with 14% achieving a complete pathologic response, and no recurrences at a median follow-up of 8.9 months.
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
In a prospective observational study of 92 older melanoma patients starting checkpoint inhibitor therapy, frailty (as assessed by the G8 tool) did not increase the risk of severe immune-related adverse events, but frail patients were hospitalized for these events significantly more often (54% vs 29%).
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Laboratory experiments showed that melanoma cells with IFNγ-JAK-STAT pathway mutations (a resistance mechanism to checkpoint inhibitors) were 7- to 22-fold more sensitive to oncolytic viruses, and about 11% of untreated cutaneous melanomas harbor such mutations, supporting a precision-medicine approach.
A new strategy for melanoma treatment: an investigation of the clinical value of the combination of immune checkpoint inhibitors and oncolytic viruses
A 2025 review of clinical trials concluded that oncolytic viruses can convert 'cold' tumors to 'hot' by increasing CD8+ T-cell density, synergizing with checkpoint inhibitors to improve response rates, while also summarizing adverse reactions and management recommendations.
Abstract LB400: Evolution of anti-viral and anti-tumor immunity in tumors in response to oncolytic virus therapy
In a mouse melanoma model, intratumoral oncolytic virus therapy increased T-cell infiltration in both injected and distant tumors and expanded tumor-specific T-cell clones, but a significant proportion of the T-cell response was anti-viral rather than anti-tumor, highlighting a limitation.
Progress in the research and development of oncolytic virus therapies
A 2026 review of oncolytic virus development notes that while OVs can remodel the tumor microenvironment and elicit systemic anti-tumor effects, their monotherapy efficacy is limited, and challenges remain in systemic delivery, biomarker identification, and manufacturing.